Novo Nordisk receives FDA approval of Saxenda® (liraglutide) injection 3 mg label
Novo Nordisk announced the FDA approved an updated product label for Saxenda® (liraglutide) injection 3 mg, including data showing that approximately half of patients on Saxenda® who lost more than or equal to 5% of their weight after 56 weeks maintained their weight loss for 3 years. April 27, 2017